Compared to the non-users, SGLT2 inhibitor users were less often female (39.3% vs 50.9%), had more chronic ischemic heart disease (16.2% vs 13.4%) and more heart failure (11.0% vs 7.1%). The gene discussed is SLC5A2; the disease is heart failure.